• Coloplast revised its 2030 ambitions to 5-7% annual organic growth, targeting an EBIT margin in the mid-20% range in constant currencies.
• Higher growth investments and external headwinds underpin the revision; the “Funding the Journey” program targets DKK 500 million in savings.
• FY 2026/27 guidance calls for 5-7% organic growth, with an EBIT margin of around 25% before special items.
• FY 2025/26 revenue rose 4% to DKK 28.94 billion, supported by Chronic Care and Interventional Urology.
• EBIT before special items fell 3% to DKK 7.45 billion, reflecting currency headwinds and pressure from Kerecis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coloplast A/S published the original content used to generate this news brief on November 03, 2026, and is solely responsible for the information contained therein.